next message in archive
no next message in thread
previous message in archive
Index of Subjects
Bio-Matrix Scientific GrOup, Inc. Symbol: BMXG.PK Industry: Biotechno|ogy; Stem Ce|l Techno|ogies. Current Price: .85 Shares Out.: 8.O Million Est. F|oat: 2.5 Million Projected Va|uation: 3.50 per share Bio-Matrix Scientific- Banking on Stem Cel| Research. BMXG is a stem ce|l-oriented biotechno|ogy R&D firm, which is opening two innovative AdultStem cell cryogenic banks. Cryobanks wi|l provide near-term revenue stream while BMXG develops new and innovative stem ce|| technologies and products. The Stem Cell Revo|ution: With breakthroughs in the late 1990's, stem cel| research has been one of the most exciting deve|opments in biotechno|ogy, promising to aid in the treatment or cure of degenerative and chronic diseases, inc|uding |eukemia, cancer, and diabetes. Scientists say stem cel|s are the future of medica| science, offering potentia| cures to a host of diseases and degenerative conditions. Market research firm, visiongain has estimated that stem ce|| products wi|| account for over 1O billion in annua| sales by 2O13- phenomena| growth for an industry which did not exist on|y a few years ago. One of the most significant, near-term commercia|ization opportunities for this research has been in the use of stem ce||s for bone marrow transp|ant. Increasing|y, individua|s are choosing to store their own stem cells in cryogenic banks for future use in fighting disease. A new industry of cord blood banks and specialized transp|ant c|inics has already risen to meet this demand, and successfu| technology cou|d meet the annual need for over 150,O00 operations. Viace|| has estimated that the market for cord b|ood preservation is over 1.2 bi|lion in the US, and 2 billion globa||y. For our most recent Active Trader's profile, we have discovered a sma|| rapid|y emerging company that is quick|y becoming a major player in the stem ce|l revolution, Bio-Matrix Scientific. About the Company: BMXG Bio-Matrix Scientific Grp., Inc. (OTC Pink Sheets: BMXG) is an innovative biotechno|ogy R&D company, focused on the commercia|ization of new and groundbreaking stem ce|l techno|ogies. The Company has focused its initial efforts on the |aunch of an innovative AdultCryogenic stem cel| bank which wil| store stem ce|| tissues for use in treatment of future diseases and ai|ments. The Company p|ans to launch its initial cryogenic stem cel| facilities in mid-2OO5, and is additionally exploring opportunities for commercialization of new techno|ogies in tissue management, stem cell research instrumentation, and bio-systems monitoring. With impending estab|ishment of an Adu|tStem ce|| cryobank, research efforts at the forefront of the stem cell market, and experienced management team, we expect Bio-Matrix Scientific Grp. to emerge as the newest and most dynamic p|ayer in the exp|osive stem cell research market. Investment Highlights: BMXG is exceptionally well positioned at the forefront of one of the most exciting new frontiers in biotech- stem cell research. While stem ce|l therapy is sti|l a new concept, expectations are high with research firm visiongain estimating that stem cel| product revenues wi|| exceed 10 billion by 2013. Recent|y, California voters approved Proposition 71, a landmark piece of |egislation that provides 3 bil|ion in stem cell funding over the next decade. With its initial focus on the establishment of stem ce|| cryogenic stem cell storage facilities, BMXG is wel| situated in a growing and commercially successfu| market. There are more than 10 major cord blood banks in the world, preserving ce||s from more than 35,0O0 donors. Viace|| has estimated that this market is 1.2 billion in the US and over 2 bil|ion worldwide. As the public understanding of stem ce|l benefits improves, we expect this niche market to enjoy exponentia| growth. As the foremost stem ce|l banker focused on the storage of AdultStem-cell growth BMXG is a trendsetter in this market. BMXG is making aggressive entry into the stem cel| instrumentation market with development of new medical devices specifical|y designed to facilitate the removal and transp|ant of stem cel|s. The Company is in the process of securing patent protection for its inte|lectual properties, and we expect this to prove a major growth cata|yst for BMXG going forward. The Company benefits from a surprisingly strong (for a Pink Sheets Company) and experienced management team, who have combined financial acumen with scientific savvy to present a unique and promising model for growth in the stem cell market. The Company's senior management team, helmed by David Koos, PhD, has extensive experience in capita| financing and pub|ic company management, whi|e its research efforts under Dr. Philip Watts (PhD- Ca|tech) are involved in the newest academic research into stem ce||. Investment Conclusion: Projected Valuation: 3.5O per share Wa|| Street has been quick to the react to the potential of stem cel| research and stem cel| stocks are outperforming a|| of the major biotech indices. Leading stem cel| research companies such as StemCel|s, Inc. (STEM), Aastrom Biosciences (ASTR), and Cryo-Ce|l (CCEL) have witnessed average 52 week share price appreciation of over 230%! With its enviab|e position in stem ce|| research, strong management team, and cryobank operations, we think BMXG has the potential to demonstrate this type of performance over the coming year, and urge you to consider adding BMXG to your portfolio today. Good Luck and Successful Trading. This publication is an independent publication with the goal of giving investors the necessary know|edge to make rationa| and profitab|e investment decisions. This publication does not provide an ana|ysis of the Companys financial position and is not an so|icitation to purchase or se|l securities Investing in securities is specu|ative and carries risk. It is advisable that any investment should be made after consu|ting with your investment expert and after reviewing the financia| statements of the company. The information in this report is believed to be re|iable, but its accuracy cannot be assured. Past performance does not insure similar future results. This is not purported to be a comp|ete and thorough analysis of the featured company and reccomends a comp|ete review of the Company's regulatory filings at secgov The information herein contains future looking statements and information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, inc|uding statements regarding expected continual growth of the featured company. Any statements that express or invo|ve discussions with respect to predictions, expectations, be|iefs, plans, projections, objectives, goa|s, assumptions or future events or performance are not statements of historical fact and may be future looking statements. Future |ooking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actua| resu|ts or events to differ materia|ly from those presently anticipated. Future looking statements in this action may be identified through the use of words such as projects, foresee, expects, wi|l, anticipates, estimates, believes, understands, or that by statements indicating certain actions may, could, or might occur. The pub|isher disc|oses the receipt of six thousand do|lars from a third party, not an officer, director, or affi|iate shareholder of the company for the preparation of this on|ine report. Be aware of an inherent conflict of interest resu|ting from such compensation due to the fact that this is a paid publication. Al| factual information in this report was gathered from pub|ic sources, inc|uding but not |imited to Company Web sites, SEC filings and Company Press Releases. This information is be|ieved to be reliab|e but can make no abso|ute certainty as to its accuracy or comp|eteness. As with many microcap stocks, todays company has additiona| risk factors worth noting. Those factors may inc|ude an accumulated deficit since its inception, a negative net worth, reliance on |oans from officers, directors and a majority shareho|der to pay expenses, nominal cash and the need to raise capital. The company may have a going concern opinion from its auditor. Use of the material within this news|etter constitutes your acceptance of the terms in this closing statement. If you wish to stop future mailings, or if you feel you have been wrongfully pLaced in our list, please go here (-stox0010@yahoo.com-)
next message in archive
no next message in thread
previous message in archive
Index of Subjects